Treatment of Acute Myeloid Leukemia: A Concise Overview
Open Access
- 31 December 2020
- journal article
- Published by Abasyn University in Abasyn Journal of Life Sciences
- p. 111-128
- https://doi.org/10.34091/ajls.3.2.11
Abstract
Acute myeloid leukemia (AML) is a disease characterized by hematopoietic and progenitor stem cells disorder, resulting in their proliferation and accumulation in bone marrow which leads to hematopoietic failure. It is an aggressive form of cancer that typically demands quick decision-making. In case of AML, the addition of drug efflux inhibitors to the chemotherapeutic regimen may improve outcomes in patients. With the advancement in treatment strategies, patients can now receive chemotherapy, radiation therapy or additional stem cell transplants. Specific genetic mutations in leukemic cells provide the direction for treatment and determine the overall survival rate of patients. Older patients have adverse treatment consequences as age is an important factor in AML prognosis. We critically reviewed multiple existing therapies for AML. Optimization of traditional therapies remain major concern of scientists. However, little bit advancement has been made in current years. There is immense need of novel and targeted therapies to treat AML and reduce its relapse chances.Keywords
This publication has 100 references indexed in Scilit:
- Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenograftsThe Journal of Experimental Medicine, 2012
- The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem CellsCancer Cell, 2012
- Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemiaNature Medicine, 2012
- IDH mutation impairs histone demethylation and results in a block to cell differentiationNature, 2012
- Targeting HIF1α Eliminates Cancer Stem Cells in Hematological MalignanciesCell Stem Cell, 2011
- Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid LeukemiaClinical Cancer Research, 2010
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- Hedgehog Signaling Is Dispensable for Adult Murine Hematopoietic Stem Cell Function and HematopoiesisCell Stem Cell, 2009
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004